Does the media refer more to GLUE or BLTE?

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Belite Bio. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for Belite Bio. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Belite Bio's score of 0.47 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MIRM or GLUE?

In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 14 mentions for Mirum Pharmaceuticals and 4 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Mirum Pharmaceuticals' score of 1.20 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GLUE or COGT?

In the previous week, Cogent Biosciences had 5 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 9 mentions for Cogent Biosciences and 4 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Cogent Biosciences' score of 0.69 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GLUE or APGE?

In the previous week, Apogee Therapeutics had 8 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 12 mentions for Apogee Therapeutics and 4 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Apogee Therapeutics' score of 0.88 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRRK or GLUE?

In the previous week, Scholar Rock had 4 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 8 mentions for Scholar Rock and 4 mentions for Monte Rosa Therapeutics. Scholar Rock's average media sentiment score of 1.34 beat Monte Rosa Therapeutics' score of 1.21 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Monte Rosa Therapeutics (GLUE) Competitors

$18.24 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$18.93 +0.69 (+3.78%)

As of 06/12/2026 06:52 PM Eastern

Compare

GLUE vs. BLTE, MIRM, COGT, APGE, and SRRK

Should you buy Monte Rosa Therapeutics stock or one of its competitors? MarketBeat compares Monte Rosa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Monte Rosa Therapeutics include Belite Bio (BLTE), Mirum Pharmaceuticals (MIRM), Cogent Biosciences (COGT), Apogee Therapeutics (APGE), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Monte Rosa Therapeutics compare to Belite Bio?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Belite Bio. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for Belite Bio. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Belite Bio's score of 0.47 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Belite Bio's return on equity of -13.14% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Belite Bio	N/A	-13.14%	-12.88%

Monte Rosa Therapeutics has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	12.46	-$38.63M	-$1.48	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Monte Rosa Therapeutics presently has a consensus price target of $32.50, suggesting a potential upside of 78.18%. Belite Bio has a consensus price target of $203.00, suggesting a potential upside of 46.93%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Monte Rosa Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Monte Rosa Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, meaning that its share price is 224% less volatile than the broader market.

Summary

Monte Rosa Therapeutics beats Belite Bio on 11 of the 15 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Mirum Pharmaceuticals has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.62	-$23.36M	-$13.61	N/A
Monte Rosa Therapeutics	$123.67M	12.46	-$38.63M	-$1.48	N/A

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Mirum Pharmaceuticals had 10 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 14 mentions for Mirum Pharmaceuticals and 4 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Mirum Pharmaceuticals' score of 1.20 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals presently has a consensus target price of $138.36, indicating a potential upside of 39.26%. Monte Rosa Therapeutics has a consensus target price of $32.50, indicating a potential upside of 78.18%. Given Monte Rosa Therapeutics' higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Mirum Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Monte Rosa Therapeutics' net margin of -302.69%. Mirum Pharmaceuticals' return on equity of -11.28% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

Summary

Mirum Pharmaceuticals beats Monte Rosa Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Cogent Biosciences?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Monte Rosa Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	12.46	-$38.63M	-$1.48	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, Cogent Biosciences had 5 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 9 mentions for Cogent Biosciences and 4 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Cogent Biosciences' score of 0.69 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Cogent Biosciences	N/A	-104.27%	-54.64%

Monte Rosa Therapeutics currently has a consensus target price of $32.50, indicating a potential upside of 78.18%. Cogent Biosciences has a consensus target price of $43.73, indicating a potential upside of 32.11%. Given Monte Rosa Therapeutics' higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Monte Rosa Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Summary

Monte Rosa Therapeutics beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Apogee Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Apogee Therapeutics had 8 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 12 mentions for Apogee Therapeutics and 4 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Apogee Therapeutics' score of 0.88 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monte Rosa Therapeutics presently has a consensus price target of $32.50, indicating a potential upside of 78.18%. Apogee Therapeutics has a consensus price target of $114.56, indicating a potential upside of 29.70%. Given Monte Rosa Therapeutics' higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Apogee Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Apogee Therapeutics' return on equity of -32.64% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Monte Rosa Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Monte Rosa Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	12.46	-$38.63M	-$1.48	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Monte Rosa Therapeutics beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scholar Rock currently has a consensus price target of $56.00, indicating a potential upside of 26.75%. Monte Rosa Therapeutics has a consensus price target of $32.50, indicating a potential upside of 78.18%. Given Monte Rosa Therapeutics' higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Scholar Rock had 4 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 8 mentions for Scholar Rock and 4 mentions for Monte Rosa Therapeutics. Scholar Rock's average media sentiment score of 1.34 beat Monte Rosa Therapeutics' score of 1.21 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

Monte Rosa Therapeutics has higher revenue and earnings than Scholar Rock. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Monte Rosa Therapeutics	$123.67M	12.46	-$38.63M	-$1.48	N/A

Summary

Scholar Rock beats Monte Rosa Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Monte Rosa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLUE vs. The Competition

Export

Metric	Monte Rosa Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.54B	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-12.32	19.82	24.21	24.42
Price / Sales	12.46	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	5.09	8.32	10.66	6.83
Net Income	-$38.63M	$23.94M	$3.57B	$337.67M
7 Day Performance	7.29%	1.84%	0.58%	1.17%
1 Month Performance	0.50%	-0.04%	1.54%	3.16%
1 Year Performance	271.49%	44.82%	25.40%	30.58%

Monte Rosa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLUE Monte Rosa Therapeutics	2.4021 of 5 stars	$18.24 flat	$32.50 +78.2%	+271.5%	$1.54B	$123.67M	N/A	90	Positive News Gap Down
BLTE Belite Bio	2.7366 of 5 stars	$141.67 -1.9%	$203.00 +43.3%	+132.0%	$5.71B	N/A	N/A	10
MIRM Mirum Pharmaceuticals	4.122 of 5 stars	$93.61 +1.2%	$137.64 +47.0%	+100.2%	$5.70B	$569.61M	N/A	140	News Coverage Positive News Analyst Forecast Insider Trade
COGT Cogent Biosciences	2.6664 of 5 stars	$32.46 -1.0%	$43.73 +34.7%	+367.5%	$5.55B	N/A	N/A	80	News Coverage
APGE Apogee Therapeutics	3.2673 of 5 stars	$89.27 -1.8%	$113.63 +27.3%	+98.6%	$5.54B	N/A	N/A	91	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLUE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. BLTE, MIRM, COGT, APGE, and SRRK

How does Monte Rosa Therapeutics compare to Belite Bio?

Summary

How does Monte Rosa Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Monte Rosa Therapeutics compare to Cogent Biosciences?

Summary

How does Monte Rosa Therapeutics compare to Apogee Therapeutics?

Summary

How does Monte Rosa Therapeutics compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. BLTE, MIRM, COGT, APGE, and SRRK

How does Monte Rosa Therapeutics compare to Belite Bio?

Does the media refer more to GLUE or BLTE?

Is GLUE or BLTE more profitable?

Which has stronger earnings and valuation, GLUE or BLTE?

Do insiders & institutionals have more ownership in GLUE or BLTE?

Do analysts recommend GLUE or BLTE?

Which has more volatility and risk, GLUE or BLTE?

Summary

How does Monte Rosa Therapeutics compare to Mirum Pharmaceuticals?

Which has preferable valuation and earnings, MIRM or GLUE?

Do institutionals & insiders believe in MIRM or GLUE?

Does the media prefer MIRM or GLUE?

Do analysts prefer MIRM or GLUE?

Which has more volatility and risk, MIRM or GLUE?

Is MIRM or GLUE more profitable?

Summary

How does Monte Rosa Therapeutics compare to Cogent Biosciences?

Which has stronger earnings and valuation, GLUE or COGT?

Does the media favor GLUE or COGT?

Is GLUE or COGT more profitable?

Do analysts recommend GLUE or COGT?

Do institutionals and insiders believe in GLUE or COGT?

Which has more risk and volatility, GLUE or COGT?

Summary

How does Monte Rosa Therapeutics compare to Apogee Therapeutics?

Does the media favor GLUE or APGE?

Do analysts prefer GLUE or APGE?

Is GLUE or APGE more profitable?

Which has more volatility & risk, GLUE or APGE?

Which has stronger earnings & valuation, GLUE or APGE?

Do institutionals & insiders believe in GLUE or APGE?

Summary

How does Monte Rosa Therapeutics compare to Scholar Rock?

Do institutionals & insiders believe in SRRK or GLUE?

Do analysts recommend SRRK or GLUE?

Does the media prefer SRRK or GLUE?

Which has more risk and volatility, SRRK or GLUE?

Is SRRK or GLUE more profitable?

Which has higher earnings & valuation, SRRK or GLUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools